Treatment and prognosis of recurrent uterine leiomyosarcomas in last 5 years

Tsuyoshi Saito¹⁾、Ryoichi Tanaka²⁾, Seiro Satohisa¹⁾, Shuetsu Abe¹⁾, Msahiro Iwasaki¹⁾ , Mizue Teramoto¹⁾, Motoki Matsuura¹⁾ , Masato Tamate¹⁾

Dept of OBGYN Sapporo Medical University¹⁾、 Gynecology Tonan Hospital²⁾

Objectives: Leiomyosarcomas in pelvis are mainly derived from uterus, however it is rare tumor and poor prognosis. Recently, several new anticancer compounds against leiomyosarcomas have been averable. In this presentation we report treatment and prognosis of uterine leiomyosarcomas in last 5 years in our instrument.

Methods: We analyzed response rate, prognosis and adverse effects of anticancer compounds for five cases of recurrent uterine leiomyosarcoma.

【Results】						【Chemotherapy after 3 rd line】		
Case	①	②	③	④	⑤	【Doses】		
Age(y)	33	61	46	52	69	PAZ	patient ① ③ 800mg/body/day	
Stage	I B	I B	I B	I B			patient ⑤ 400mg/body/day (< 70 yd, BMI > 18)	
Primary chemotherapy (courses)	AI(2) →GD(4)	GD(3)		GD(6)	GD(3)	TBR	1.2 mg/m ² /24hr every 3 weeks	
PDS (M)	27	20	17	12	11	ERI	1.4 mg/m ² day1, 8 every 3 weeks	
Recurrence site	abdominal cavity	RS1	LS9	LS9	retro peritoneum	【 Adverse event 】		
Resection surgery	ileocecal resection partial cystectomy	VATS	VATS	VATS	none	PAZ	elevation of ALT; hypertension; proteinuria; Grade 0 nausea; dizziness	Grade 0 1case, Grade 1 1case, Grade 3 1case Grade 1 1case, Grade 2 1case, Grade 3 1case 1case, Grade 1 1case, Grade 3 1case Grade 1 1case, Grade 2 2case Grade 1 1case, Grade 2 2case
Chemotherapy for recurrence	PAZ(4)	ADM(3)	ADM(3) PAZ(9) TRB(3) ERI(5)		ADM(3) PAZ(3) ERI(3) TRB(6)	TBR	elevation of ALT; leukopenia;Grade 1 nausea; dizziness;	Grade 1 1case, Grade 2 1case 1case, Grade 2 1case Grade 1 2case Grade 1 2case
After treatment of recurrence						ERI	leukopenia;Grade 2 nausea; dizziness;	1case, Grade 3 1case Grade 0 1case, Grade 1 2case Grade 0 1case, Grade 1 2case
PDS (M)	41	21	4	59	3 *			
OS (M)	50	29	22	59	16			
Re-recurrence site		Sternum Pelvic LN	RS8 subcutaneous					
Surgery of re-recurrence	Small bowel resection partial cystectomy		VATS			【Effect】		
						PAZ	PR 1case	PD 1case
OS (M)	78	49	39	71	27	TBR	SD 1case	PD 1case
Turning out	AWD	DOD	AWD	NED	AWD	ERI	SD 1case	PD 1case

AI; Adriamycin+Ifosfamide GD; Gemcitabine+Docetaxel VATS; Video-assisted thorascopic surgery
ADM; Adriamycin PAZ; Pazopanib TBR; Trabectedin
ERI; Eribulin AWD; Alive with disease DOD; Dead of disease NED; No evidence disease

▪ Conclusions: In this study, only one case showed disease free survival who underwent tumor section surgery recurrent uterine leiomyosarcoma, however severe adverse effects was not found in new anticancer compounds.